NorthStar Medical Radioisotopes expands operations at University of Missouri Research Reactor
NorthStar Medical Radioisotopes, a nuclear medicine company based out of Madison, Wis., announced this week it is enhancing its production operations at the University of Missouri Research Reactor (MURR). The move will help the company quadruple its capacity to dispense molybdenum-99 (Mo-99).
Von Gahlen International has been contracted to do the work at MURR, which will include designing and installing a new high-capacity filling line. Work is expected to last from November to “the first half of 2017.”
George Messina, NorthStar chairman, president and CEO, said in a prepared statement that the company is now investing more than $3 million in developing its new process for producing Mo-99 without the use of highly enriched uranium (HEU).
“This increased capacity will enable us to meet the anticipated demand for our non-HEU Mo-99 and our RadioGenix isotope separation system,” George Messina, NorthStar chairman, president and CEO, said in a prepared statement. “Our recent progress toward commercialization of our production processes, and the encouraging feedback we’ve received from the marketplace, justify this investment. We are confident it will pay dividends for years to come.”
Previous coverage of NorthStar Medical Radioisotopes can be read here and here.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.